| Literature DB >> 31997801 |
Nina Dietzmeyer1, Maria Förthmann1, Claudia Grothe1, Kirsten Haastert-Talini1.
Abstract
Surgical treatment of peripheral nerve injuries is still a major challenge in human clinic. Up to now, none of the well-developed microsurgical treatment options is able to guarantee a complete restoration of nerve function. This restriction is also effective for novel clinically approved artificial nerve guides. In this review, we compare surgical repair techniques primarily for digital nerve injuries reported with relatively high prevalence to be valuable attempts in clinical digital nerve repair and point out their advantages and shortcomings. We furthermore discuss the use of artificial nerve grafts with a focus on chitosan-based nerve guides, for which our own studies contributed to their approval for clinical use. In the second part of this review, very recent future perspectives for the enhancement of tubular (commonly hollow) nerve guides are discussed in terms of their clinical translatability and ability to form three-dimensional constructs that biomimick the natural nerve structure. This includes materials that have already shown their beneficial potential in in vivo studies like fibrous intraluminal guidance structures, hydrogels, growth factors, and approaches of cell transplantation. Additionally, we highlight upcoming future perspectives comprising co-application of stem cell secretome. From our overview, we conclude that already simple attempts are highly effective to increase the regeneration supporting properties of nerve guides in experimental studies. But for bringing nerve repair with bioartificial nerve grafts to the next level, e.g. repair of defects > 3 cm in human patients, more complex intraluminal guidance structures such as innovatively manufactured hydrogels and likely supplementation of stem cells or their secretome for therapeutic purposes may represent promising future perspectives.Entities:
Keywords: bioartificial nerve graft; biological nerve graft; cell transplantation; cellular products; luminal structures; peripheral nerve repair
Year: 2020 PMID: 31997801 PMCID: PMC7059590 DOI: 10.4103/1673-5374.271668
Source DB: PubMed Journal: Neural Regen Res ISSN: 1673-5374 Impact factor: 5.135
Advantages and shortcomings of surgical digital nerve repair approaches currently used in clinical practice with relatively high prevalence
| Treatment strategy | Advantages | Shortcomings |
|---|---|---|
| Direct coaptation | • Method of choice (Dahlin and Wiberg, 2017) | • Only when tension-free (Houschyar et al., 2016; Dahlin and Wiberg, 2017) |
| Autologous nerve graft | • Up to 5 cm gap (Siemers and Houschyar, 2017; Wieringa et al., 2018) | • Not off-the-shelf |
| Autologous muscle-in-vein graft | • Up to 6 cm gap (Sabongi et al., 2015) | • Not off-the-shelf |
| Processed nerve allograft | • Off-the-shelf product (López-Cebral et al., 2017; Siemers and Houschyar, 2017) | • Disease transmission (He et al., 2015; Siemers and Houschyar, 2017) |
| Artificial nerve graft | • No donor site morbidity (Muheremu and Ao, 2015; Belanger et al., 2016) | • Approved for use ≤ 3 cm gap (Belanger et al., 2016; Houshyar et al., 2019) |
Advantages and shortcomings and rating of the translatability of recently researched approaches for enhancing nerve guidance channels with biomicking luminal fillers
| Biomimicking approach | Advantages | Shortcomings | Translatability |
|---|---|---|---|
| Natural ECM components | • Representing neurotropic factors (Gonzalez-Perez et al., 2017; Wieringa et al., 2018) | • Lack of structural guidance (Sarker et al., 2018a) | √ (chemical modification) |
| Advanced Hydrogels | • Representing neurotropic factors (Gonzalez-Perez et al., 2018) | • Lack of cell binding peptides (Sarker et al., 2018b; Wieringa et al., 2018) | √ |
| Linear guidance structures | • Structural guidance (Wieringa et al., 2018; Houshyar et al., 2019) | • Production costs | √ (material of approved conduits) |
| Cell transplantation | • Release of neurotropic and neurotrophic factors (Muheremu and Ao, 2015; Belanger et al., 2016; Sarker et al., 2018b) | • Donor site morbidity for the use of primary Schwann cells (Jones et al., 2016; Gonzalez-Perez et al., 2018) | ? |
| Neurotrophic factors | • Biomimicking (Belanger et al., 2016; Sarker et al., 2018b) | • Short bioactivity/Half-life time (Belanger et al., 2016; Li et al., 2017; Sarker et al., 2018b) | √ (protection during scaffold manufacturing) |
ECM: Extracellular matrix; √: probable; ?: under debate.